Cargando…

Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol

BACKGROUND: Fluticasone propionate/salmeterol xinafoate (FP/SAL) is an inhaled corticosteroid (ICS) and long-acting β(2)-agonist (LABA) combination, indicated for the regular treatment of children (aged >4 years) with asthma that is inadequately controlled with ICS monotherapy plus as-needed shor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pitrez, Paulo Marcio, Nanthapisal, Sira, Castro, Ana Paula Beltran Moschione, Teli, Chirag, P G, Abhijith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Asthma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450074/ https://www.ncbi.nlm.nih.gov/pubmed/37620110 http://dx.doi.org/10.1136/bmjresp-2023-001706

Ejemplares similares

Adverse effects of salmeterol in asthma: a neuronal perspective
por: Lommatzsch, M, et al.
Publicado: (2009)

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials
por: Jin, Xiaofen, et al.
Publicado: (2020)

Evaluation of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Combination on Exercise in Pediatric and Adolescent Patients with Asthma
por: Murray, John J, et al.
Publicado: (2011)

One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
por: Chapman, Kenneth, et al.
Publicado: (2021)

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
por: Houghton, Catherine M, et al.
Publicado: (2007)

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone
por: Bateman, Eric D, et al.
Publicado: (2014)

The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis
por: Guan, Renzheng, et al.
Publicado: (2019)

Salmeterol plus fluticasone propionate versus fluticasone propionate plus montelukast: a randomised controlled trial investigating the effects on airway inflammation in asthma
por: Pavord, Ian, et al.
Publicado: (2007)

Relationship of Pneumocystis antibody responses to paediatric asthma severity
por: Rayens, Emily, et al.
Publicado: (2021)

Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD)
por: Mills, Hilla, et al.
Publicado: (2022)

Safety and Efficacy of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler Compared with Fluticasone Propionate/Salmeterol Diskus in Patients with Chronic Obstructive Pulmonary Disease
por: Koser, Andras, et al.
Publicado: (2010)

Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort
por: de Boer, Geertje, et al.
Publicado: (2021)

The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD
por: Yawn, Barbara P, et al.
Publicado: (2010)

Dexamethasone/salmeterol/fluticasone-propionate: Invasive pulmonary Aspergillosis: case report
Publicado: (2021)

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β(2) agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial
por: Busse, William W, et al.
Publicado: (2013)

Fluticasone propionate-salmeterol versus inhaled corticosteroids plus montelukast: outcomes study in pediatric patients with asthma
por: Stanford, Richard H, et al.
Publicado: (2012)

Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial
por: Singh, Dave, et al.
Publicado: (2015)

Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization
por: Ainali, Nina Maria, et al.
Publicado: (2020)

Efficacy and Safety of Fluticasone Furoate/Vilanterol Compared With Fluticasone Propionate/Salmeterol Combination in Adult and Adolescent Patients With Persistent Asthma: A Randomized Trial
por: Woodcock, Ashley, et al.
Publicado: (2013)

Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2011)

Cost-effectiveness of combination fluticasone propionate–salmeterol 250/50 μg versus salmeterol in severe COPD patients
por: Dalal, Anand A, et al.
Publicado: (2010)

Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate–severe asthma
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2017)

Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study
por: Wang, Wen, et al.
Publicado: (2023)

Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
por: Yasui, Hideki, et al.
Publicado: (2018)

Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study
por: Craig, Simon, et al.
Publicado: (2022)

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
por: Atsuta, Ryo, et al.
Publicado: (2018)

Phenotypic characteristics and asthma severity in an East African cohort of adults and adolescents with asthma: findings from the African severe asthma project
por: Kirenga, Bruce, et al.
Publicado: (2020)

Non-inferiority efficacy comparison of mometasone furoate/formoterol versus fluticasone propionate/salmeterol combination therapies in subjects with persistent asthma
por: Bernstein, David I, et al.
Publicado: (2010)

Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study
por: Bousquet, Jean, et al.
Publicado: (2017)

The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device
por: Tashkin, Donald P., et al.
Publicado: (2021)

Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
por: Jackson, David J, et al.
Publicado: (2021)

Development of a conceptual model of childhood asthma to inform asthma prevention policies
por: Adibi, Amin, et al.
Publicado: (2021)

Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study
por: Chipps, Bradley E, et al.
Publicado: (2021)

Economic burden of asthma in Singapore
por: Finkelstein, Eric A, et al.
Publicado: (2021)

Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma
por: Bauer, Rebecca N, et al.
Publicado: (2019)

Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma
por: Lee, Lulu K, et al.
Publicado: (2020)

Chlamydia pneumoniae-induced tumour necrosis factor alpha responses are lower in children with asthma compared with non-asthma
por: Smith-Norowitz, Tamar Anne, et al.
Publicado: (2018)

Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
por: Ohar, Jill A, et al.
Publicado: (2014)

Urbanisation and asthma in low-income and middle-income countries: a systematic review of the urban–rural differences in asthma prevalence
por: Rodriguez, Alejandro, et al.
Publicado: (2019)

Reslizumab as add-on therapy in patients with refractory asthma
por: Virchow, J Christian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u12gbs4a8g6g5skhjkiskc5r8b